Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting ...
A previous study demonstrated that power against the (unobserved) true effect for the primary end point (PEP) of most phase III oncology trials is low, suggesting an increased risk of false-negative ...
Department of Health and Aging Australia. The Review of the AR-DRG Classification System Development Process: Brisbane, QLD, Australia: PricewaterhouseCoopers; 2009. 2. Klein-Hitpass U, ...
The main purpose of this paper is to clarify relations and distinctions between several approaches suggested in the statistical literature for analysing structures in correlation matrices, i.e. of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results